Get started
Author

Janette Contreras‐De Lama

Observed name: Janette Contreras-De Lama
ORCID: 0009-0005-9032-7676
Observed ORCID: 0009-0005-9032-7676
OpenAlex ID: A5037874386
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
2021 · Abhijeet Jakate, Andrew M. Blumenfeld, et al. · Headache The Journal of Head and Face Pain · 70
PDF
Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
2023 · Aubrey Manack Adams, Susan Hutchinson, et al. · The Journal of Headache and Pain · 22
PDF
Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study
2023 · Richard B. Lipton, Michel Lanteri-Minet, et al. · The Journal of Headache and Pain · 16
PDF
Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE
2023 · Richard B. Lipton, Janette Contreras-De Lama, et al. · Neurology and Therapy · 16
PDF
Treatment Patterns and Unmet Needs in the Acute Treatment of Migraine.
2020 · Richard B Lipton, Dawn C Buse, et al. · PubMed · 4
Characterizing Pre-headache (Prodrome) Features of Migraine Attacks: Results From the CaMEO Study (S4.004)
2022 · Todd J. Schwedt, Stephanie J. Nahas, et al. · Neurology · 3
Real-World Effectiveness of Ubrogepant for the Acute Treatment of Migraine When Used in Combination With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study (P10-2.003)
2022 · Aubrey Manack Adams, Janette Contreras-De Lama, et al. · Neurology · 3
Pharmacokinetics, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Coadministration With Preventive Monoclonal Antibody Treatment (1250)
2021 · Abhijeet Jakate, Andrew M. Blumenfeld, et al. · Neurology · 3
Within-Person Analysis of Ubrogepant Treatment of Mild Versus Moderate-Severe Headache Pain during a Phase 3 Long-Term Safety Extension Trial (S31.006)
2022 · Richard B. Lipton, David W. Dodick, et al. · Neurology · 2
Safety and Tolerability of Ubrogepant Within Various Demographic and Clinical Characteristic Subgroups (1249)
2021 · Jessica Ailani, Brad Klein, et al. · Neurology · 2
Exploratory Efficacy Results from the TANDEM Trial: Safety, Tolerability, and Efficacy of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine (P8-12.002)
2025 · Andrew M. Blumenfeld, Molly Yizeng He, et al. · Neurology · 1
Treatment Satisfaction and Optimization With Real-World Use of Ubrogepant for the Acute Treatment of Migraine in Combination With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study (P10-2.001)
2022 · Janette Contreras-De Lama, Aubrey Manack Adams, et al. · Neurology · 1
Within-Person Consistency of Acute Treatment Success With Ubrogepant: Results From a Long-term Safety Study (P2-2.003)
2022 · Charlie Iaconangelo, Daniel Serrano, et al. · Neurology · 1
Opioid use, disability, and patient‐reported cognitive impairment in migraine: Multi‐country results from the Chronic Migraine Epidemiology and Outcomes—International Study
2026 · Elizabeth Leroux, Dawn C. Buse, et al. · Headache The Journal of Head and Face Pain
PDF
Real-world Acute Treatment Optimization for Migraine with Ubrogepant: Results from the COURAGE II Study (P8-15.015)
2026 · Stephanie Nahas, Brittany Mays, et al. · Neurology
Characterizing a Population Reporting Menstrually Related Migraine: Multi-country Results from the Chronic Migraine Epidemiology and Outcomes–international (CaMEO-I) Study (P8-15.002)
2026 · Jessica Ailani, Jelena Pavlovic, et al. · Neurology
Impact of the Number of Previous Triptans Trialed on Triptan Effectiveness, Tolerability, and Healthcare Resource Use: Multicountry Results from the CaMEO-I Study (P6-15.018)
2026 · Zaza Katsarava, Karen Carr, et al. · Neurology
Opioid Use, Disability, and Cognition in Migraine: Multi-Country Results From the Chronic Migraine Epidemiology and Outcomes – International Study (S35.009)
2025 · Elizabeth Leroux, Dawn Buse, et al. · Neurology
Characterizing Within Participant Consistency of Prodromal Symptoms in Migraine: Results from the PRODROME Trial Screening Period (P8-12.001)
2025 · Todd Schwedt, Andrew Blumenfeld, et al. · Neurology
Gaps in Acute Treatment Optimization in Participants with Migraine: Results from the US Cohort of the Chronic Migraine Epidemiology and Outcomes—International (CaMEO-I) Study (S22.003)
2024 · Todd Schwedt, Dawn Buse, et al. · Neurology
Real-World Effectiveness of Ubrogepant for the Acute Treatment of Migraine in Combination With OnabotulinumtoxinA Preventive: Results From the COURAGE Study
2022 · Richard B. Lipton, Ella Engstrom, et al. · Toxicon
Works count: 21
Citation count: 144
H-index: 4
I10-index: 4
Year
Topic
Type